ADOCIA Announces the Release of Its Universal Registration Document for the Year 2023
An electronic copy of this document is available on the company’s website (www.adocia.com) as well as on the website of the AMF (www.amf-france.org). Hard copies are available upon request at the company’s headquarters located 115, avenue Lacassagne, 69003 Lyon.
The following documents are included in the Universal Registration Document (document d’enregistrement universel):
- the 2023 annual financial report, which includes the 2023 Management Report,
- the 2023 Board of Directors’ report on corporate governance,
- the reports from the statutory auditors and information on their fees,
- the description of the share buy-back program.
About
The company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) The BioChaperone® technology for the development of new generation insulins and products combining different hormones; 2) AdOral®, an oral peptide delivery technology; 3) AdoShell®, an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation; and 4) AdoGel®, a long-acting drug delivery platform.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240429715023/en/
CEO
contactinvestisseurs@adocia.com
+33 (0)4 72 610 610
www.adocia.com
Ulysse Communication
adocia@ulysse-communication.com
+ 33 (0)6 87 88 47 26
Source: